The landscape of clinical trials for heavily pretreated multiple myeloma: opportunity for more randomization?

被引：0
|
作者：
Kapur, Rohan [1 ]
Mccarron, John [2 ]
Rajeeve, Sridevi [3 ]
Mohyuddin, Ghulam Rehman [4 ]
机构：
[1] Maimonides Hosp, Brooklyn, NY USA
[2] Univ Utah, Salt Lake City, UT USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY USA
[4] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
来源：
LEUKEMIA & LYMPHOMA | 2025年 / 66卷 / 02期
关键词：
THERAPY;
D O I：
10.1080/10428194.2024.2411625
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：355 / 357
页数：3
相关论文
共 50 条
  • [41] Current clinical trials in multiple myeloma
    不详
    ONCOLOGY-NEW YORK, 2004, 18 (02): : 196 - +
  • [42] The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma
    Syed Maaz Tariq
    Al-Ola Abdallah
    Aaron Goodman
    Douglas Sborov
    Ghulam Rehman Mohyuddin
    Alec Britt
    Clinical Hematology International, 2023, 5 (2-3) : 170 - 176
  • [43] Bendamustine salvage for relapsed - refractory multiple myeloma: a retrospective analysis of outcomes in heavily pretreated patients
    Singh, Aakanksha
    Agrawal, Narendra
    Haldar, Rohan
    Bhurani, Dinesh
    Raychoudhari, Jyoti Shankar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S211 - S211
  • [44] Successful treatment with belantamab mafodotin in a heavily pretreated patient with multiple myeloma and liver extramedullary disease
    Sgherza, Nicola
    Curci, Paola
    Di Carlo, Gabriella
    Grande, Domenica
    Capozzi, Alessandro
    Ingravallo, Giuseppe
    De Marco, Luca
    Ferreri, Paolo
    Musto, Pellegrino
    LEUKEMIA & LYMPHOMA, 2024, 65 (10) : 1528 - 1531
  • [45] Role of Pegfilgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone
    Cerchione, Claudio
    Catalano, Lucio
    Nappi, Davide
    Pareto, Anna Emanuele
    Pane, Fabrizio
    Martinelli, Giovanni
    BLOOD, 2021, 138
  • [46] Final results of a phase I study of carfilzomib, lenalidomide, and dexamethasone for heavily pretreated multiple myeloma
    Isamu Sugiura
    Kenshi Suzuki
    Masaki Ri
    Takaaki Chou
    Naoki Takezako
    Kazutaka Sunami
    Tadao Ishida
    Tohru Izumi
    Shuji Ozaki
    Yoshihisa Shumiya
    Shinsuke Iida
    International Journal of Hematology, 2020, 111 : 57 - 64
  • [47] Pepaxto: A New Peptide-Drug Conjugate for Heavily Pretreated Relapsed and Refractory Multiple Myeloma
    Jessee, Jeremiah K.
    ANNALS OF PHARMACOTHERAPY, 2022, 56 (08) : 951 - 957
  • [48] Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan
    Suzuki, Kenshi
    Ri, Masaki
    Chou, Takaaki
    Sugiura, Isamu
    Takezako, Naoki
    Sunami, Kazutaka
    Ishida, Tadao
    Izumi, Tohru
    Ozaki, Shuji
    Shumiya, Yoshihisa
    Ota, Kenji
    Iida, Shinsuke
    CANCER SCIENCE, 2017, 108 (03) : 461 - 468
  • [49] A real-world study of belantamab mafodotin in a heavily pretreated population of multiple myeloma patients
    Bird, Sarah
    Bishop, Ellouise
    Panopoulou, Katerina
    Saso, Radovan
    Mir, Farheen
    Stern, Simon
    Kaiser, Martin
    Boyd, Kevin
    Pawlyn, Charlotte
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 60 - 61
  • [50] Lenalidomide (Revlimid), Bortezomib (Velcade) and Dexamethasone (RVD) for Heavily Pretreated Relapsed or Refractory Multiple Myeloma
    Jimenez-Zepeda, Victor H.
    Reece, Donna E.
    Trudel, Suzanne
    Chen, Christine
    Kukreti, Vishal
    BLOOD, 2011, 118 (21) : 1266 - 1267
12345